Objectives: This research of XTRM‐FIT Coronary Stent System in combination with Tirofiban in the treatment of 35 cases of elderly Acute Coronary Syndrome (ACS) had a satisfactory result. The report is as follows: Methods: Choose ACS 60 cases under PCI, according to random number table the test was randomly divided into two groups: Group A (XTRM ‐ FIT + Tirofiban) had 30 cases, male 16 cases, female 14 cases; Group B (XTRM ‐ FIT) had 30 cases, male 15 cases, female 15 cases. Choose the same stent brand for each patient. There were no statistically significant in difference compared (P>0.05). According to the angiography results of coronary artery stenosis degree, the degree of stenosis >75% was defined as PCI treatment lower limit. The size of stent was chose by clinical doctor. After coronary artery guiding wire through Occlusion lesions, then give injection load for Tirofiban 10 mug/kg, the intravenous injection is completed within 3 minutes. For the 70‐year‐old or older patients or stroke patients within 2 years, the dosing is reduced 20%, then the micro‐injection pump continuous to inject 36h with 0.15 mug/(kg.min). In the process of PCI, intravenous injection heparin 50 U/kg, an extra 1000 U with each more than 1h.The presence of stenocardia, any abnormal changes of electrocardiogram, myocardial enzyme, platelet count, hemoglobin, hematokrit (HCT), etcoutpatient follow‐up or telephone follow‐up for 30 days about the incidence of stenocardia, the incidence of subacute thrombosis, the rate of MACE, rehospitalization rate. Using SPSS 10.0 statistical software for data processing. P<0.05 for the difference was statistically significant. Results: In the two groups, there were no statistically significant (P>0.05) for the number of target vessel, Stenosis degree, the number of stent implantation, the Peak pressure of stent release, operating time, PCI success rate, etc. The rate of acute instent thrombosis occurred for the two groups were 0 and 3.33% respectively (P<0.05).Bleeding complications: between the two groups (P>0.05).The platelet count, hemoglobin, Hematokrit (HCT) change. Between the two groups (P>0.05). 30‐day follow‐up results after PCI: the rate of target vascular reconstruction, subacute thrombosis, MACE rate and rehospitalization between the two groups (P<0.05). Conclusions: XTRM‐FIT coronary stent system, is the latest generation coronary artery stent which is manufactured by Blue Medical Devices B.V (the Netherlands). It adopts unique "Dylyn" biological coating technology, reduces the intravascular endothelial hyperplasia and inflammatory reaction. Short, both XTRM‐FIT Coronary Stent System in combination with Tirofiban and only stent implantation all have good security, but have significant differences for effectiveness. For the combination therapy, the incidence of stenocardia, MACE rate, the incidence of acute and subacute thrombosis and hospitalization rates, etc. were significantly lower.
Peiliang, L., Xuan, L., & Lei, M. (2014). GW25-e1572 XTRM-FIT Coronary Stent System in combination with Tirofiban in the treatment of elderly Acute Coronary Syndrome. Journal of the American College of Cardiology, 64(16), C149. https://doi.org/10.1016/j.jacc.2014.06.685